` 2181 (Mabpharm Ltd) vs Hang Seng (Hong Kong) Comparison - Alpha Spread

M
2181
vs
H
Hang Seng (Hong Kong)

Over the past 12 months, Mabpharm Ltd has outperformed Hang Seng (Hong Kong), delivering a return of +16% compared to the Hang Seng (Hong Kong)'s +5% growth.

Stocks Performance
2181 vs Hang Seng (Hong Kong)

Loading
2181
Hang Seng (Hong Kong)
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
2181 vs Hang Seng (Hong Kong)

Performance Gap Between 2181 and HSI
HIDDEN
Show

Performance By Year
2181 vs Hang Seng (Hong Kong)

Loading
2181
Hang Seng (Hong Kong)
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Mabpharm Ltd vs Peers

Hang Seng (Hong Kong)
2181
RYI
AVGR
BROG
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Mabpharm Ltd
Glance View

Market Cap
3B HKD
Industry
Biotechnology

Mabpharm Ltd. engages in the research, development, and manufacture of monoclonal antibody drugs for the treatment of cancer and autoimmune diseases. The company is headquartered in Taizhou, Jiangsu. The company went IPO on 2019-05-31. The firm's main products include omalizumab (CMAB007), cetuximab (CMAB009) and infliximab (CMAB008). The firm mainly conducts its businesses in China market.

Mabpharm Ltd Intrinsic Value
HIDDEN
Show
Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett